Title of Invention

A COMPOSITION COMPRISING BIOTIN AND VITAMIN C

Abstract The present invention relates to the use of biotin alone, preferably, however, with vitamin C or a derivative thereof, for the preparation of a cosmetic composition or of a pharmaceutical composition for skin-lightening purposes, for the elimination of skin color irregularities and for the treatment of senile lentigines.
Full Text

USE OF BIOTIN OR A BIOTIN DERIVATIVE FOR SKIN LIGHTENING PURPOSES AND FOR THE TREATMENT OF SENILE LENTIGINES
The present invention relates to the use of biotin or a biotin derivative alone, preferably with vitamin C or a vitamin C derivative, for the preparation of a pharmaceutical composition or a cosmetic composition for the treatment of senile lentigines, for smoothening skin color irregularities and/or for lightening natural skin color.
Senile lentigines are dark spots on the skin arising from the aging of the skin. They are a consequence of various aging processes, which are accelerated by incident light radiation. The skin thus appears inhomogeneous with respect to its color.
Tanning is a natural protective function of the skin with varying degrees of distinction in different ethnic groups. In many cultural circles a light skin tone is considered attractive so that a need for lightening the natural skin color arises.
Compositions for skin lightening purposes are known, such as e.g. hydroquinone, kojic acid, arbutin, vitamin C as well as various plant extracts. One problem with many compositions, however, is that apart from a lightening of the skin or an elimination of the senile lentigos (liver spots, senile lentigines) also side effects such as e.g. skin irritations can occur. Plant extracts that lead to fewer skin irritations are generally not sufficiently effective.
There is a need for additional compositions, particularly cosmetic compositions that are well tolerated by the skin and yet are effective for skin lightening, for the treatment of senile lentigines and for smoothening skin color irregularities. The compositions should be at least as effective, preferably more effective than the familiar skin lightening compositions.
Biotin is a known active ingredient, which can be found in numerous cosmetic formulations and pharmaceutical compositions. Biotin is a compound of the following formula:


that can occur in eight different stereoisomeric forms. Biotin is in particular the D-(+)-biotin, i.e. the compound (3aS, 4S, 6aR)-2-oxohexahydrothieno[3,4-d]-imidazole-4-valeric acid of the following formula:
The effectiveness of the use of biotin in skin lightening applications has not been known until now.
Pursuant to the invention it was surprisingly found that biotin exhibits a skin-lightening effect and thus can be used for the treatment of senile lentigos, for smoothening skin color irregularities as well as for lightening the natural skin tone.
The invention hence makes the use of biotin available for the preparation of a composition for lightening the natural skin tone, for smoothening skin color irregularities and/or for treating senile lentigines.
The term "biotin" pursuant to the invention relates to the eight stereoisomers of the formula:


either in a stereochemically pure form or as any random mixture of two or more stereoisomers. Particularly preferred pursuant to the invention is the D-(+)-biotin of the formula:

Biotin derivatives are known to the expert. These are compounds that are converted into biotin in vitro, particularly however in vivo. Lipophilic biotin derivatives, which generally penetrate the skin better than biotin itself, yet achieve equivalent effects as biotin, are particularly preferred. Apart from biotin, pursuant to the invention also biotin esters are particularly preferred, from which after penetration through the stratum corneum biotin is released again by the skin's own enzyme systems. Particularly preferred pursuant to the invention are biotin esters of the formulas I and II, which are deduced from biotin as follows:







The topical formulations pursuant to the invention preferably contain one or more conventional fatty substances as additives, e.g., vegetable oils, liquid paraffin oils, isoparaffin oils, synthetic hydrocarbons, di-n-alkyl esters, fatty acids, fatty alcohols, ester oils, hydroxy-carboxylic acid esters, di-carboxylic acid esters, diol esters, symmetrical, non-symmetrical or cyclic esters or carbonic acid esters with fatty alcohols, mono-, di- and tri-fatty acid esters with glycerin, waxes and silicon compounds.
The fatty substances are generally present in the topical composition in a quantity of 0.1 to 50% by weight, preferably from 0.1 to 20% by weight, in particular from 0.1 to 15% by weight (in relation to the entire composition, respectively).
The topical compositions can contain other additives, such as, for example, one or more surface-active substances as emulsifying or dispersing agents. Suitable examples of such emulsifying or dispersing agents are known.
The emulsifying agents can be present in the topical compositions for example in parts from 0.1 to 25% by weight, preferred from 0.5 to 15% by weight, in relation to the entire composition.
The topical compositions can likewise contain conventional sun-screen agents as additives, for example conventional UV-A and/or UV-B filters. An overview of conventional UV-A and UV-B filters, which can also be employed in the compositions pursuant to the invention, can be found for example in EP-A 1 081 140. Pursuant to the invention of course also novel sun protection filters that are disclosed in this document for the first time can be used in the inventive compositions.
Suitable organic, mineral or modified mineral sun-screen filters are also disclosed in WO 01/64177, to which we refer here as well.
If desired, the inventive compositions can also contain protein hydrolyzates or derivatives thereof as well as suitable mono-, oligo- or poly-saccharides or their derivatives, as additives, as they are e.g. revealed in WO 01/64177. Further suitable additives and auxiliary agents, such as vitamins, pro-vitamins and vitamin precursors, allantoin, bisabolol, anti-oxidants, ceramides and pseudo-ceramides, triterpenes, monomer catechines, thickening agents, plant glycosides,

structure-providing substances (structuring agents), dimethylisosorbide, solvents, swelling and penetration adjuvants, perfume oils, pigments and colorants for dying the composition, substances for adjusting the pH value, complexing agents, opacifiers, pearly luster substances, expanding agents, film-forming. emulsion-stabilizing, thickening or adhesive polymers, especially cationic, anionic as well as non-ionic polymers are likewise revealed in WO 01/64177, which is incorporated herein by reference in so far.
The compositions are preferably formulated such that they are suitable for topical applications. Topical application occurs preferably at least once a day, e.g. two or three times a day. The treatment duration generally lasts at least two days until the desired effect has been achieved. The treatment duration can also take several weeks or months.
The quantity of the composition that is to be applied depends on the concentration of the active ingredient in the composition as well as the severity of the disease that is to be treated and/or the desired cosmetic success. In the case of a pharmaceutical usage generally the quantity of the active ingredient to be used per application is higher than in the case of a cosmetic use. An effective amount for the application depends on the condition of the skin, the person to be treated as well as the severity and type of the skin discoloration to be treated and other factors, which are known to the attending physician or cosmetician. For example application can occur such that a cream is applied to the skin. A cream is usually applied in a suitable quantity of 2 mg cream/cm2 skin. The applied quantity however is not critical, and if no treatment success should be achieved with a certain quantity of the applied active ingredient then the applied amount can certainly be increased, for example by using topical formulations with higher concentrations.
Pursuant to the invention the active ingredient can be formulated as such or also in encapsulated form, for example in liposomal form. Liposomes are beneficially formed with lecithins without or with the addition of sterols or phytosterols. The encapsulation of the active ingredient can occur alone or together with other active ingredients.
The inventive composition contains a suitable quantity of 0.0001% by weight to approximately 50% by weight of biotin in relation to the total weight of composition. It is more preferred if biotin is present in a suitable quantity of 0.01% by weight to about 20% by weight, even more

preferred in a suitable quantity of about 0.01% by weight to about 1% by weight, in particular in a suitable quantity of about 0.1% by weight in relation to the total weight of the composition.
With respect to the type and preparation of the topical compositions as well as the disclosure of exemplary additives, we would like to refer to relevant literature, e.g. to NOWAK G.A., Cosmetic Preparations - Volume 2, Cosmetic Preparations - Recipes, Starting Substances, Scientific Basis (Verlag for chem. Industrie H. Ziolkowsky KG, Augsburg, Germany).
It is likewise possible to formulate biotin as an oral composition, for example in form of pills, tablets, capsules, which e.g. contain a granule or pellet, as liquid oral formulations or as an additive to foods, which is known to the expert in principle. Suitable methods and additives, with which the orally administered compositions can be produced pursuant to the invention, are disclosed e.g. in the standard work "Remington: The Science and Practice of Pharmacy", Lippincott, Williams and Wilking (Publisher) 2000, which is incorporated herein by reference.
Traditional excipients such as micro-crystalline cellulose, sodium citrate, calcium carbonate, disodium or dipotassium phosphate, sodium or potassium phosphate, glycine, agents to promote breakdown such as starch or alginic acid, binding agents such as polyvinyl-pyrrolidone, saccharose, gelatin or acacia gum, slip additives such as magnesium stearate, sodium lauryl sulfate or talcum can be used in tablet production as conventional additives for oral compositions, especially for tablets. If the composition is filled in gel capsules, conventional auxiliary agents for the production of granules are lactose or milk sugar as well as polyethylene glycols with a high molecular weight. Further additives for other oral formulations, and in particular for the formulation as additives to foodstuffs, are known to the expert, and we refer to the relevant literature, e.g. "Principles of Food Engineering" (Grundzuge der Lebensmitteltechnik), Horst-Dieter Tscheuschner (publisher), 2nd, newly revised Edition Hamburg: Behr's 1996.
In case of an oral composition, the content of the active ingredient (i.e. the biotin and/or biotin derivative) in the composition is generally 1% to 90%, preferably 10% to 80%, e.g. 50% or more. Administration occurs such that the desired effect is achieved and depends on the condition of the patient, the type and severity of the skin discoloration to be treated, etc. and

can easily be determined by the expert. A common daily dosage of the active ingredient is in the range from 0.1 (µ/day to 50 mg/day, e.g. 20 µg/day to 2 mg/day.
Pursuant to the invention it was furthermore surprisingly found that apart from its own effectiveness for skin lightening purposes biotin exhibits a surprisingly high skin-lightening effect when it is administered together with vitamin C or a vitamin C derivative.
Vitamin C derivatives are known, and pursuant to the invention they are interpreted as all compounds that release vitamin C in vivo or in vitro, as well as solvates, hydrates and salts thereof. As examples of vitamin C derivatives e.g. glucosides of ascorbic acid and phosphates of ascorbic acid and in particular magnesium ascorbyl phosphate, sodium ascorbyl phosphate, calcium ascorbyl phosphate, potassium ascorbyl phosphate and mixed salts, such as e.g. sodium magnesium ascorbyl phosphate or sodium calcium ascorbyl phosphate, can be mentioned. Especially the phosphates frequently exist as hydrates, wherein the dihydrate form is the most common. Biotin is particularly preferred pursuant to the invention together with sodium ascorbyl phosphate, and the most preferred in form of the dihydrate, as it is available for example from Roche Vitamins AG under the product name STAY-C 50.
It has been known that vitamin C exhibits a skin-lightening effect, yet it was not known that a combination of biotin and vitamin C and/or a vitamin C derivatives have a skin-lightening effect that is considerably more distinct than the skin-lightening effect of vitamin C alone.
Pursuant to the invention the vitamin C and/or the derivatives thereof can be incorporated in the same formulation in which also the biotin is present. Vitamin C and/or the derivative thereof in a topical composition is preferably used in a quantity of 0.001% by weight to about 50% by weight in relation to the total weight of the composition. It is more preferred if vitamin C and/or the derivative thereof is used in a topical composition in a quantity of 0.01% by weight to about 20% by weight, even more preferred in a quantity of about 0.1% by weight to about 15% by weight, e.g. 1 to about 5% by weight, such as e.g. 3% by weight, in relation to the overall weight of the composition. With respect to the quantity of vitamin C and/or the derivative thereof in an oral composition we would like to refer to the aforementioned explanations of biotin which also applies to the quantity and dosage of vitamin C and/or the derivative thereof.

Pursuant to the invention, the term "composition" also includes an embodiment in which the composition is present in two separate parts, wherein one part contains the active ingredient biotin and the other part the active ingredient vitamin C or a derivative thereof. The two separate parts of the composition can each be topically applied or orally ingested, yet it is also possible that one separate part of the composition is applied topically and the other part of the composition is administered orally so that in the inventive composition e.g. one separate part contains the active ingredient biotin and is applied topically, while the other separate part contains the active ingredient vitamin C or a derivative thereof and is administered orally or wherein the separate part of the composition that contains the active ingredient biotin is administered orally and the separate part of the composition that contains the active ingredient vitamin C and/or a derivative thereof is applied topically.
For the preparation of the separate parts of the composition, the additives, active ingredients and the quantities of the respective additives and active ingredients contained in the separate parts, reference can be made to the aforementioned examples of topical and oral formulations with biotin, which also apply to the inventive embodiment in which the composition exists in two separate parts, each containing an active substance. For the quantity of vitamin C and/or the derivative thereof in one of the separate parts, reference can be made to the aforementioned embodiments wherein the composition is not present in the form of two separate parts, but where both active ingredients are present in a single composition.
To the extent that the composition contains both biotin and vitamin C and/or a derivative thereof, the weight ratio of vitamin C and/or the derivative thereof to biotin is preferably 500:1 to 1:500, more preferred 100:1 to 1:100, and in particular 30:1 to 1:30. It is furthermore preferred that the quantity of vitamin C and/or the derivative thereof is higher in the composition than the quantity of biotin. The information above applies both to embodiments in which biotin and vitamin C and/or a derivative thereof are present together in the mixture and to embodiments in which the composition consists of two separate parts, wherein the one part contains the active ingredient biotin and the other part the active ingredient vitamin C and/or a derivative thereof.
To the extent that the active ingredients mentioned here can be present as hydrates or solvates, the hydrates and solvates are also included in the present invention.




Parts A) and B) were heated separately from each other to 75°C, respectively, while stirring. As soon as parts A) and B) were homogeneous, part B) was added to part A) while stirring. The mixture was homogenized at 11,000 RPM for 30 seconds. Part C) was pre-warmed to 65°C and added to the homogenized mixture of A) and B). The mixture of A), B) and C) was cooled down to 40°C, and part D) was added. The mixture was cooled down to the ambient temperature (25°C) while stirring.
The resulting cream had a pH value of 7.0 and had a viscosity (Brookfield RVT, 25°C, Spindle 5, 10 RPM) of approximately 20,000 cP.
Apart from a cream pursuant to the invention, a placebo was produced correspondingly, in which neither sodium ascorbyl phosphate nor biotin were present, as well as a cream with 0.1% biotin exclusively and a cream with 3% sodium ascorbyl phosphate exclusively.
2. Test Example
39 female subjects were divided into three groups of 13 persons each. The subjects applied twice a day for three months a test formulation on the left and a second test formulation on the right halves of their faces as well as on the left and the right backs of their hands. The test formulations were coded and corresponded to a placebo formulation and a formulation with the desired test substance. The three groups hereby tested the creams produced above with 3% sodium ascorbyl phosphate (STAY-C 50), 0.1% biotin and with a mixture of 3% sodium ascorbyl phosphate and 0.1% biotin.

PCT/EP2004/009048 DSM IP ASSETS B.V.
CLAIMS:
1. Use of biotin, a biotin derivative or a salt thereof for manufacturing a composition for
lightening the skin and/or smoothening skin color irregularities.
2. Use of biotin, a biotin derivative or a salt thereof for manufacturing a composition for
lightening the skin, smoothening skin color irregularities and/or treating senile
lentigos, wherein the biotin, the biotin derivative or the salt thereof are used together
with vitamin C or a vitamin C derivative.
3. Use according to claim 1 or 2, wherein the biotin salt is an alkali salt, an earth alkali
salt, an ammonium salt or a hydrochloride of the biotin or the biotin derivative.
4. Use according to any of claims 1 to 3, wherein the biotin derivative is a compound of
formula I or formula II:


5. Use according to any of claims 1 to 4, wherein the composition is for topical
administration.
6. Use according to any of claims 1 to 4, wherein the composition is for oral
administration.
7. Use according to any of claims 1 to 6, wherein the composition is a cosmetic
composition.
8. Use according to any of claims 1 to 6, wherein the composition is a pharmaceutical
composition.
9. Use according to any of claims 1 to 8, wherein the biotin, the biotin derivative or the
salt thereof is present at a concentration of 0.001 to 50% by weight, in relation to the
weight of the composition.
10. Use according to claim 9, wherein the biotin, the biotin derivative or the salt thereof
is present at a concentration of 0.01 to 1% by weight, in relation to the weight of the
composition.
11. Use according to any of claims 2 to 10, wherein the biotin, the biotin derivative or the
salt thereof is used together with sodium ascorbyl phosphate or a hydrate thereof, in
particular the dihydrate thereof.
12. Use according to any of claims 2 to 11, wherein the vitamin C or the vitamin C
derivative is present at a concentration of 0.001 to 50% by weight, in relation to the
weight of the composition.
13. Use according to claim 12, wherein the vitamin C or the vitamin C derivative is
present at a concentration of 0.1 to 15% by weight, in relation to the weight of the
composition.
14. Use according to any of claims 2 to 13, wherein the weight ratio of the vitamin C or
the vitamin C derivative, respectively, to the biotin, the biotin derivative or the salt
thereof is is 500:1 to 1:500.

15. Use according to claim 14, wherein the weight ratio of the vitamin C or the vitamin C
derivative, respectively, to the biotin, the biotin derivative or the salt thereof is 30:1 to
1:30.
16. Use according to any of claims 2 to 15, wherein the composition is arranged such
that the biotin, the biotin derivative or the salt thereof and the vitamin C or the
vitamin C derivative, respectively, are physically separated.
17. Use according to claim 16, wherein one of the active ingredients is formulated for
oral administration and the other is formulated for topical administration.
Dated this 22 day of February 2006


Documents:

652-chenp-2006 amended claims 06-05-2011.pdf

652-chenp-2006 amended pages of specification 06-05-2011.pdf

652-chenp-2006 form-3 06-05-2011.pdf

652-CHENP-2006 OTHER PATENT DOCUMENT 1 06-05-2011.pdf

652-chenp-2006 other patent document 2 06-05-2011.pdf

652-chenp-2006 power of attorney 06-05-2011.pdf

652-chenp-2006 examination report reply received 06-05-2011.pdf

652-chenp-2006 correspondence others 29-03-2011.pdf

652-chenp-2006-abstract.pdf

652-chenp-2006-claims.pdf

652-chenp-2006-correspondence-others.pdf

652-chenp-2006-description(complete).pdf

652-chenp-2006-drawings.pdf

652-chenp-2006-form 1.pdf

652-chenp-2006-form 3.pdf

652-chenp-2006-form 5.pdf

652-chenp-2006-pct.pdf


Patent Number 247848
Indian Patent Application Number 652/CHENP/2006
PG Journal Number 22/2011
Publication Date 03-Jun-2011
Grant Date 26-May-2011
Date of Filing 22-Feb-2006
Name of Patentee DSM IP ASSETS B.V.
Applicant Address Het Overloon 1, NL-6411 TE Heerlen
Inventors:
# Inventor's Name Inventor's Address
1 JERMANN, Roland Kundmatt 10, CH-4242 Laufen
2 LUTHER, Helmut Allmendweg 1, 79639 Grenzach-Wyhlen
PCT International Classification Number A61K
PCT International Application Number PCT/EP2004/009048
PCT International Filing date 2004-08-12
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 03018730.6 2003-08-26 EUROPEAN UNION